Tag Archives: Sanofi

Sanofi Responds to UK’s Value-Based Assessment Plans

By Leela Barham. The UK’s National Institute for Health and Care Excellence (NICE) set out their proposals for value-based assessment (VBA) in March 2014.  VBA is what value-based pricing (VBP) has essentially morphed into. Much work is going on behind closed doors to inform responses as the consultation closing date of the 20th June 2014 […]
Posted in Europe, Global, Guest Blog, healthcare, Op-Ed, pricing, Regulatory | Also tagged , , , , | Leave a comment

Ad Agency Encourages Pharma Marketers to Reboot

People tell you who they are, but we ignore it – because we want them to be who we want them to be. – Don Draper At the beginning of the Reboot Camp – held at New York City’s Alexandria Center on April 12 – Intouch Solutions’ CEO Faruk Capan declared the days of Don […]
Posted in Advertising, Agency Insight, Emerging Markets, FDA, healthcare, leadership, Marketing, Patient Communication, patient education, People, Regulatory, Sales, social media, Strategy, Technology | Also tagged , , , , , , , , , , , | 1 Comment

New Non-Profit Alliance of Big Pharma Firms

By Amy Ritter. Ten biopharmaceutical companies announced the formation of a nonprofit organization called TransCelerate BioPharma, the mission of which is to accelerate the development of new medicines by identifying and solving common drug development challenges.
Posted in Biotech, Deals, Guest Blog | Also tagged , , , , , , , , , | Leave a comment

Sanofi's Aubagio to Square Off Against MS Injectables

The most obvious competitors for Sanofi’s Aubagio, the second oral multiple sclerosis (MS) drug to receive FDA approval, would appear to be Novartis’ Gilenya, and Biogen Idec’s hotly anticipated BG-12, which has a PDUFA date scheduled for December 28. Both Gilenya and BG-12 are administered orally as opposed to injected, but execs at Genzyme – […]
Posted in FDA, pricing, Regulatory, Safety, Strategy | Also tagged , , , | 2 Comments

BIO 2012: The Case for Collaboration

Rodney King died on Sunday, but his famous question lives on: “Can we all get along?” At BIO 2012, the proposition seems to be: “Can we all just collaborate?”
Posted in Biotech, Europe, Events, FDA, Global, healthcare, IP, leadership, People, R&D, Regulatory, Strategy, Technology | Also tagged , , , , , , | Leave a comment
  • Categories

  • Meta